Hannah Baker - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Hannah Baker's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Hannah Baker
Verified
Medical Writer, reparerx.com
Austin
Beats
Women’s Health , Healthcare , Social And Health Inequality
Content
By Caitlin Cano, Sarah Connell, Hannah Baker Verified| Do512@ On Tuesday, August 2, Suerte will host Chef Dylan Salisbury of Tatsu-Ya for the August Taquero Takeover! For this one-night collaboration, the team will be serving a Smoked Kalua Pork Taco with Tiki XO Sauce and Avocado Salsa, available for dine-in only. Chef Salisbury pulled inspiration for the taco from a quintessential Hawaiian dish featuring pork wrapped in a banana leaf and cooked in an "imu" (an underground oven that is one of civilization's most ancient cooking structures).
By Caitlin Cano, Hannah Baker Verified| Do512@ Send me updates when these bands announce new shows Your entry will also register you for Do512, where you'll get the best of what to do in Austin every week. Terms & Conditions.
By Caitlin Cano, Sarah Connell, Hannah Baker Verified| Do512@ On Tuesday, August 2, Suerte will host Chef Dylan Salisbury of Tatsu-Ya for the August Taquero Takeover! For this one-night collaboration, the team will be serving a Smoked Kalua Pork Taco with Tiki XO Sauce and Avocado Salsa, available for dine-in only. Chef Salisbury pulled inspiration for the taco from a quintessential Hawaiian dish featuring pork wrapped in a banana leaf and cooked in an "imu" (an underground oven that is one of civilization's most ancient cooking structures).
Company Info
reparerx.com
Repare Therapeutics is a clinical-stage precision oncology company based in Quebec, Canada, founded in 2016. The company focuses on discovering and developing novel therapeutics through a proprietary synthetic lethality approach, targeting genomic instability and DNA damage repair. Utilizing its CRISPR-enabled SNIPRx® platform, Repare Therapeutics systematically identifies and validates targets for cancer therapies. The company has a diverse product pipeline aimed at addressing cancers with significant unmet medical needs and is actively engaged in clinical trials for these candidates. Repare Therapeutics is also involved in strategic partnerships, including the out-licensing of its discovery platforms to DCx Biotherapeutics. Listed on the Nasdaq under the ticker symbol RPTX, Repare Therapeutics operates with a team of 51 to 200 employees and has additional operations in Switzerland. The company is committed to advancing cancer treatment through innovative research and development.
'+1 857-412-7018
Founded: 2016